The First Report of Iranian Registry of Patients with Spinal Muscular Atrophy

Background: Insufficient amounts of survival motor neuron protein is leading to one of the most disabling neuromuscular diseases, spinal muscular atrophy (SMA). Before the current study, the detailed characteristics of Iranian patients with SMA had not been determined. Objective: To describe the key...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuromuscular diseases 2023-01, Vol.10 (2), p.211-225
Hauptverfasser: Mansouri, Vahid, Heidari, Morteza, Bemanalizadeh, Maryam, Azizimalamiri, Reza, Nafissi, Shahriar, Akbari, Masood Ghahvechi, Barzegar, Mohammad, Moayedi, Ali Reza, Badv, Reza Shervin, Mohamadi, Mahmood, Tavasoli, Ali Reza, Amirsalari, Susan, Khajeh, Ali, Inaloo, Soroor, Fatehi, Farzad, Hosseinpour, Sareh, Babaei, Meisam, Hosseini, Seyed Ahmad, Mahdi Hosseiny, Seyyed Mohammad, Fayyazi, Afshin, Hosseini, Firoozeh, Toosi, Mehran Beiraghi, Khosroshahi, Nahid, Ghabeli, Homa, Biglari, Habibeh Nejad, Kakhki, Simin Khayatzadeh, Mirlohi, Seyed Hossein, Bidabadi, Elham, Mohammadi, Bahram, Omrani, Abdolmajid, Sedighi, Mostafa, Vafaee-Shahi, Mohammad, Rasulinezhad, Maryam, Hoseini, Seyyed Mohamad, Movahedinia, Mojtaba, Rezaei, Zahra, Karimi, Parviz, Farshadmoghadam, Hossein, Anvari, Saeed, Yaghini, Omid, Nasiri, Jafar, Zamani, Gholamreza, Ashrafi, Mahmoud Reza
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Insufficient amounts of survival motor neuron protein is leading to one of the most disabling neuromuscular diseases, spinal muscular atrophy (SMA). Before the current study, the detailed characteristics of Iranian patients with SMA had not been determined. Objective: To describe the key demographic, clinical, and genetic characteristics of patients with SMA registered in the Iranian Registry of SMA (IRSMA). Methods: IRSMA has been established since 2018, and the demographic, clinical, and genetic characteristics of patients with SMA were recorded according to the methods of treat neuromuscular disease (TREAT-NMD) project. Results: By October 1, 2022, 781 patients with 5q SMA were registered. Of them, 164 patients died, the majority of them had SMA type 1 and died during the first 20 months of life. The median survival of patients with type 1 SMA was 23 months. The consanguinity rate in 617 alive patients was 52.4%, while merely 24.8% of them had a positive family history. The most common type of SMA in live patients was type 3. Morbidities were defined as having scoliosis (44.1%), wheelchair dependency (36.8%), tube feeding (8.1%), and requiring mechanical ventilation (9.9%). Most of the registered patients had a homozygous deletion of SMN1, while the frequency of patients with higher copy numbers of SMN2, was less in more severe types of the disease. Earlier onset of the disease was significantly seen in patients with lower copy numbers of SMN2. The neuronal apoptosis inhibitory protein (NAIP) gene deletion was associated with a higher incidence of more severe types of SMA, higher dependency on ventilators, tube feeding, and earlier onset of the disease. Conclusions: The IRSMA is the first established Iranian nationwide registry of patients with SMA. Using this registry, decision-makers, researchers, and practitioners can precisely understand the epidemiology, characteristics, and genetics of patients with SMA in Iran.
ISSN:2214-3599
2214-3602
DOI:10.3233/JND-221614